Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (4) : biopharmaceuticals

CordenPharma to Acquire AmbioPharm to Expand Peptide Manufacturing Platform

CordenPharma to Acquire AmbioPharm to Expand Peptide Manufacturing Platform
05/27/2026 | Companies
CordenPharma has announced plans to acquire AmbioPharm, a move aimed at strengthening its peptide active pharmaceutical ingredient (API) manufacturing capabilities and expanding its global production network. The acquisition will enhance CordenPharma’s existing peptide platform by adding...
AmbioPharm, API manufacturing, Astorg, biopharmaceuticals, biotech industry, BNP Paribas, Carlyle Group, CDMO, China pharmaceutical manufacturing, clinical peptide supply, commercial peptide production, contract development and manufacturing organization, CordenPharma, global peptide supply, hybrid peptide synthesis, LPPS, North Augusta facility, peptide API, peptide APIs, peptide commercialization, peptide drug development, peptide manufacturing, peptide medicines, peptide platform, pharmaceutical acquisition, pharmaceutical industry, pharmaceutical manufacturing, Shanghai manufacturing, SPPS, TAPS technology, U.S. peptide manufacturing

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
Mabwell (688062.SH), an innovation-focused biopharmaceutical company with an integrated value chain, has announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its novel LILRB4/CD3 T cell engager (TCE) bispecific antibody,...
6MW5311, acute myeloid leukemia, AML, biopharmaceuticals, biotechnology, bispecific antibody, cancer research, CD3, chronic myelomonocytic leukemia, clinical trials, CMML, cytotoxicity, drug development, FDA, hematologic malignancies, immune synapse, immunotherapy, IND application, LILRB4, Mabwell, MM, multiple myeloma, NMPA, oncology, preclinical studies, stem cell transplantation, steric hindrance, T cell engager, targeted therapy, TCE technology, tumor inhibition

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey
04/03/2025 | Companies
In 2006, Tomas Cihlar was well aware that, despite initial successes with combination therapy, HIV continued to be a global challenge with limited treatment options. At the time, he had been researching virology at Gilead for 12 years, and the first once-daily, single-tablet regimen for HIV...
antiviral therapy, biopharmaceuticals, biotechnology, breakthrough medicine, clinical trials, drug discovery, drug resistance, Gilead, global health, healthcare innovation, HIV, HIV prevention, HIV research, HIV treatment, medical innovation, medical science, pharmaceutical development, Tomas Cihlar, viral capsid, virology

Gilead Sciences Leads in Innovation & Responsibility

Gilead Sciences Leads in Innovation & Responsibility
03/20/2025 | Companies
We’re honored to once again be recognized among the top five most just companies in the biopharmaceutical industry in the United States. This recognition highlights our continued dedication to responsible business practices and empowering our workforce to contribute to a healthier global community....
biopharmaceuticals, corporate responsibility, drug development, employee empowerment, Foster City California, Gilead Sciences, global health, global operations, healthcare, innovative medicines, life-threatening illnesses, medical innovation, medical research, responsible business, top biopharma companies


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com